Skip to main content
Erschienen in: Der Urologe 2/2013

01.02.2013 | Leitthema

Ätiologie und Pathophysiologie der benignen Prostatahyperplasie

verfasst von: PD Dr. A. Roosen, C. Gratzke, A. Herrlemann, G. Magistro, F. Strittmatter, P. Weinhold, S. Tritschler, C.G. Stief

Erschienen in: Die Urologie | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Ätiologie der benignen Prostatahyperplasie (BPH) ist nach wie vor unklar. Es handelt sich um eine häufige Erkrankung, die in ihrer vollen klinischen Ausprägung exklusiv die menschliche Spezies betrifft und am ehesten multifaktorieller Genese ist. Verantwortlich gemacht werden: inflammatorische Prozesse, die sich vorwiegend im Stroma abspielen und von hier aus eine Proliferation des gesamten Drüsengewebes der Transitionalzone in Gang setzen, eine Dysbalance von Androgenen, Östrogenen und deren Rezeptoren, eine direkte proliferative Wirkung von Hyperinsulinämie und Hypercholesterinämie beim metabolischen Syndrom sowie ein autosomal-dominanter Erbgang. Der Detrusor kompensiert den erhöhten urethralen Widerstand durch eine muskuläre Hypertrophie. Die resultierende Minderbeweglichkeit der Blasenwand ist Ursache der Entleerungsstörungen, während eine elektrophysiologische Instabilität des hypertrophierten Detrusors und eine gesteigerte Rekrutierung afferenter Fasern Ursachen der Speicherstörungen sind.
Literatur
1.
Zurück zum Zitat Isaacs JT (1994) Etiology of benign prostatic hyperplasia. Eur Urol 25(Suppl 1):6–9PubMed Isaacs JT (1994) Etiology of benign prostatic hyperplasia. Eur Urol 25(Suppl 1):6–9PubMed
2.
Zurück zum Zitat Marberger M, Roehrborn CG, Marks LS (2006) Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 91(4):1323–1328PubMedCrossRef Marberger M, Roehrborn CG, Marks LS (2006) Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 91(4):1323–1328PubMedCrossRef
3.
Zurück zum Zitat McNeal JE (1978) Origin and evolution of benign prostatic enlargement. Invest Urol 15(4):340–345PubMed McNeal JE (1978) Origin and evolution of benign prostatic enlargement. Invest Urol 15(4):340–345PubMed
4.
Zurück zum Zitat Castro P, Giri D, Lamb D, Ittmann M (2003) Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55(1):30–38PubMedCrossRef Castro P, Giri D, Lamb D, Ittmann M (2003) Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55(1):30–38PubMedCrossRef
5.
Zurück zum Zitat Schauer IG, Rowley DR (2008) Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 72(1):205–213PubMedCrossRef Schauer IG, Rowley DR (2008) Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 72(1):205–213PubMedCrossRef
6.
Zurück zum Zitat Khadra A, Fletcher P, Luzzi G et al (2006) Interleukin-8 levels in seminal plasma in chronic prostatitis/chronic pelvic pain syndrome and nonspecific urethritis. BJU Int 97(5):1043–1046PubMedCrossRef Khadra A, Fletcher P, Luzzi G et al (2006) Interleukin-8 levels in seminal plasma in chronic prostatitis/chronic pelvic pain syndrome and nonspecific urethritis. BJU Int 97(5):1043–1046PubMedCrossRef
7.
Zurück zum Zitat Macoska JA (2011) Chemokines and BPH/LUTS. Differentiation 82(4–5):253–260 Macoska JA (2011) Chemokines and BPH/LUTS. Differentiation 82(4–5):253–260
8.
Zurück zum Zitat Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51(5):1202–1216PubMedCrossRef Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51(5):1202–1216PubMedCrossRef
9.
Zurück zum Zitat Delongchamps NB, de la Roza G, Chandan V et al (2008) Evaluation of prostatitis in autopsied prostates – is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 179(5):1736–1740PubMedCrossRef Delongchamps NB, de la Roza G, Chandan V et al (2008) Evaluation of prostatitis in autopsied prostates – is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 179(5):1736–1740PubMedCrossRef
10.
Zurück zum Zitat Mishra VC, Allen DJ, Nicolaou C et al (2007) Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 100(2):327–331PubMedCrossRef Mishra VC, Allen DJ, Nicolaou C et al (2007) Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 100(2):327–331PubMedCrossRef
11.
Zurück zum Zitat Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82(4–5):184–199 Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82(4–5):184–199
12.
Zurück zum Zitat Roberts RO, Jacobson DJ, Rhodes T et al (2004) Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 61(2):124–131PubMedCrossRef Roberts RO, Jacobson DJ, Rhodes T et al (2004) Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 61(2):124–131PubMedCrossRef
13.
Zurück zum Zitat Hammarsten J, Damber JE, Karlsson M et al (2009) Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 12(2):160–165PubMedCrossRef Hammarsten J, Damber JE, Karlsson M et al (2009) Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 12(2):160–165PubMedCrossRef
14.
Zurück zum Zitat Ellem SJ, Risbridger GP (2009) The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci 1155:174–186PubMedCrossRef Ellem SJ, Risbridger GP (2009) The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci 1155:174–186PubMedCrossRef
15.
Zurück zum Zitat Sugiyama N, Barros RP, Warner M et al (2010) ER beta: recent understanding of estrogen signaling. Trends Endocrinol Metab 21(9):545–552PubMedCrossRef Sugiyama N, Barros RP, Warner M et al (2010) ER beta: recent understanding of estrogen signaling. Trends Endocrinol Metab 21(9):545–552PubMedCrossRef
16.
Zurück zum Zitat Yang R, Ma YX, Chen LF et al (2010) Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia. Asian J Androl 12(5):735–743PubMedCrossRef Yang R, Ma YX, Chen LF et al (2010) Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia. Asian J Androl 12(5):735–743PubMedCrossRef
17.
Zurück zum Zitat Ozden C, Ozdal OL, Urgancioglu G et al (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51(1):199–206PubMedCrossRef Ozden C, Ozdal OL, Urgancioglu G et al (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51(1):199–206PubMedCrossRef
18.
Zurück zum Zitat Parsons JK, Bergstrom J, Barrett-Connor E (2008) Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 101(3):313–318PubMedCrossRef Parsons JK, Bergstrom J, Barrett-Connor E (2008) Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 101(3):313–318PubMedCrossRef
19.
Zurück zum Zitat Wang Z, Olumi AF (2011) Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation 82(4–5):261–271 Wang Z, Olumi AF (2011) Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation 82(4–5):261–271
20.
Zurück zum Zitat Pertseva MN, Shpakov AO, Plesneva SA et al (2003) A novel view on the mechanisms of action of insulin and other insulin superfamily peptides: involvement of adenylyl cyclase signaling system. Comp Biochem Physiol B Biochem Mol Biol 134(1):11–36PubMedCrossRef Pertseva MN, Shpakov AO, Plesneva SA et al (2003) A novel view on the mechanisms of action of insulin and other insulin superfamily peptides: involvement of adenylyl cyclase signaling system. Comp Biochem Physiol B Biochem Mol Biol 134(1):11–36PubMedCrossRef
21.
Zurück zum Zitat Li W, Wu CL, Febbo PG et al (2007) Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol 171(4):1189–1198PubMedCrossRef Li W, Wu CL, Febbo PG et al (2007) Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol 171(4):1189–1198PubMedCrossRef
22.
Zurück zum Zitat Landsberg L (1986) Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 61(236):1081–1090PubMed Landsberg L (1986) Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 61(236):1081–1090PubMed
23.
Zurück zum Zitat Davis HR, Veltri EP (2007) Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 14(3):99–108PubMedCrossRef Davis HR, Veltri EP (2007) Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 14(3):99–108PubMedCrossRef
24.
Zurück zum Zitat Jiang M, Fernandez S, Jerome WG et al (2010) Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell Death Differ 17(3):469–481PubMedCrossRef Jiang M, Fernandez S, Jerome WG et al (2010) Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell Death Differ 17(3):469–481PubMedCrossRef
25.
Zurück zum Zitat Sanda MG, Beaty TH, Stutzman RE et al (1997) Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol 157(3):876–879PubMedCrossRef Sanda MG, Beaty TH, Stutzman RE et al (1997) Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol 157(3):876–879PubMedCrossRef
26.
Zurück zum Zitat Pearson JD, Lei HH, Beaty TH et al (2003) Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology 61(4):781–785PubMedCrossRef Pearson JD, Lei HH, Beaty TH et al (2003) Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology 61(4):781–785PubMedCrossRef
27.
Zurück zum Zitat Hocaoglu Y, Herrmann K, Walther S et al (2013) Contraction of the anterior prostate is required for the initiation of micturition. BJU (in press) Hocaoglu Y, Herrmann K, Walther S et al (2013) Contraction of the anterior prostate is required for the initiation of micturition. BJU (in press)
28.
Zurück zum Zitat Uckert S, Schultheiss D, Geismar U et al (2008) Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 71(3):526–530PubMedCrossRef Uckert S, Schultheiss D, Geismar U et al (2008) Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 71(3):526–530PubMedCrossRef
29.
Zurück zum Zitat Gosling JA, Dixon JS (1980) Structure of trabeculated detrusor smooth muscle in cases of prostatic hypertrophy. Urol Int 35(5):351–355PubMedCrossRef Gosling JA, Dixon JS (1980) Structure of trabeculated detrusor smooth muscle in cases of prostatic hypertrophy. Urol Int 35(5):351–355PubMedCrossRef
30.
Zurück zum Zitat Steers WD (2002) Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4(Suppl 4):7–18 Steers WD (2002) Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4(Suppl 4):7–18
31.
Zurück zum Zitat Jiang M, Strand DW, Franco OE et al (2011) PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation 82(4–5):181–123 Jiang M, Strand DW, Franco OE et al (2011) PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation 82(4–5):181–123
Metadaten
Titel
Ätiologie und Pathophysiologie der benignen Prostatahyperplasie
verfasst von
PD Dr. A. Roosen
C. Gratzke
A. Herrlemann
G. Magistro
F. Strittmatter
P. Weinhold
S. Tritschler
C.G. Stief
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Die Urologie / Ausgabe 2/2013
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-012-3083-3

Weitere Artikel der Ausgabe 2/2013

Der Urologe 2/2013 Zur Ausgabe

Mitteilungen der DGU

Termine

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.